Sandy Keenan edits Viewpoint and news articles for Spectrum. She is a New York-based journalist who has enjoyed a richly varied career — as reporter, editor and newsroom manager — with The New York Times and Newsday. She started out as a sportswriter for the Miami Herald, then moved on to Sports Illustrated and then Newsday, where she transitioned from covering Knicks, Mets and Yankees games on deadline into editing and over to news. She eventually became Newsday‘s assistant managing editor in charge of news, investigations and narrative projects. More recently, with the Times, she served as environment editor, deputy sports editor and a staff writer for the Home & Garden section.
Sandy Keenan
Contributing Editor
Spectrum
Explore more from The Transmitter
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.